Peters et al. analysed T-DM1 in a phase 2 study with HER2-OE (IHC, 2+ and 3+) and previously treated NSCLC patients and found no treatment responses in IHC 2+ cohort. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.